Lodelcizumab, a relatively discovered monoclonal antigen, represents a potentially solution in the effort against recurrent migraines. Unlike many available therapies that focus pain immediately, lodelcizumab uniquely inhibits CGRP, a key protein involved in migraine development. This unique way

A Deep Dive into the SGN-70 Antibody

Vorsetuzumab represents a promising treatment in tumor treatment, specifically targeting the CD22 protein expressed on blood cancers. Developed by Seattle Genetics, Vorsetuzumab functions as an ADCC mechanism inducer,